The DOI matches its Crossref record; 274 of the 274 references it cites were found in a registry or an index.
Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
Abstract
Epigenetic regulation of gene expression is mediated through alterations in the DNA methylation status, covalent modifications of core nucleosomal histones, rearrangement of histones, and by RNA interference. It is now abundantly clear that deregulation of epigenetic mechanisms cooperates with genetic alterations in the development and progression of cancer and leukemia. Epigenetic deregulation affects several aspects of tumor cell biology, including cell growth, cell cycle control, differentiation, DNA repair, and cell death. This raises the strong possibility that reversing deregulated epigenetic mechanisms may be an effective treatment strategy for leukemia and cancer. This treatment strategy may either be designed to separately or collectively target the specific perturbations in the epigenetic mechanisms found in human hematologic malignancies. The following review describes our current understanding of the important deregulated epigenetic mechanisms and the preclinical and clinical development of epigenetic and chromatin modifiers in the therapy of these disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–274 of 274
Aron, J. L., Parthun, M. R., Marcucci, G., Kitada, S., Mone, A. P., Davis, M. E., Shen, T., Murphy, T., Wickham, J., Kanakry, C., et al. (2003) · Blood · doi:10.1182/blood-2002-12-3794 · Cited by 171
Lübbert, M. (2000) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-59696-4_9 · Cited by 169
Histone-Deacetylase Inhibitors for the Treatment of Cancer
Lindemann, R. K., Gabrielli, B. G., & Johnstone, R. W. (2004) · Cell Cycle · doi:10.4161/cc.3.6.927 · Cited by 168
Mie Lee, Y., Kim, S.-H., Kim, H.-S., Jin Son, M., Nakajima, H., Jeong Kwon, H., & Kim, K.-W. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02787-0 · Cited by 165
Suberoylanilide Hydroxamic Acid as a Potential Therapeutic Agent for Human Breast Cancer Treatment
Huang, L., & Pardee, A. B. (2000) · Molecular Medicine · doi:10.1007/bf03401823 · Cited by 164
Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis
Daser, A., & Rabbitts, T. H. (2004) · Genes & Development · doi:10.1101/gad.1195504 · Cited by 163
DNA methyltransferases get connected to chromatin
Burgers, W. A., Fuks, F., & Kouzarides, T. (2002) · Trends in Genetics · doi:10.1016/s0168-9525(02)02667-7 · Cited by 161
Henderson, C. J., Mizzau, M., Paroni, G., Maestro, R., Schneider, C., & Brancolini, C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213093200 · Cited by 159
Byrd, J. C., Shinn, C. A., Ravi, R. K., Willis, C. R., Waselenko, J. K., Flinn, I. W., Dawson, N. A., & Grever, M. R. (1999) · Blood · doi:10.1182/blood.v94.4.1401 · Cited by 156
Coffey, D. C., Kutko, M. C., Glick, R. D., Butler, L. M., Heller, G., Rifkind, R. A., Marks, P. A., Richon, V. M., & LaQuaglia, M. P. (2001) · PubMed · Cited by 154
DNA Damage-induced Translocation of the Werner Helicase Is Regulated by Acetylation
Blander, G., Zalle, N., Daniely, Y., Taplick, J., Gray, M. D., & Oren, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m210479200 · Cited by 154
Tam, W., Hughes, S. H., Hayward, W. S., & Besmer, P. (2002) · Journal of Virology · doi:10.1128/jvi.76.9.4275-4286.2002 · Cited by 151
Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance.
Kantharidis, P., El‐Osta, A., DeSilva, M., Wall, D. M., Hu, X. F., Slater, A. A., Nadalin, G., Parkin, J. D., & Zalcberg, J. R. (1997) · PubMed · Cited by 144
Clinical trial on 5-AZA-2′-deoxycytidine in patients with acute leukemia
Momparler, R. L., Rivard, G., & Gyger, M. (1985) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(85)90052-x · Cited by 143
Almenara, J., Rosato, R., & Grant, S. (2002) · Leukemia · doi:10.1038/sj.leu.2402535 · Cited by 141
Up-Regulation of p21WAF1/CIP1 by Histone Deacetylase Inhibitors Reduces Their Cytotoxicity
Burgess, A., Pavey, S. J., Warrener, R., Hunter, L.-J. K., Piva, T. J., Musgrove, E. A., Saunders, N. A., Parsons, P. G., & Gabrielli, B. G. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12311-5 · Cited by 138
中川内, 哲. (2004) · Institutional Repositories DataBase (IRDB) · Cited by 138
Chronic Oral Administration of CI-994: A Phase I Study
Prakash, S., Foster, B. J., Meyer, M., Wozniak, A., Heilbrun, L. K., Flaherty, L. E., Zalupski, M. M., Radulovic, L. L., Valdivieso, M., & LoRusso, P. M. (2001) · Investigational New Drugs · doi:10.1023/a:1006489328324 · Cited by 136
Lucas, D. M., Davis, M. E., Parthun, M. R., Mone, A. P., Kitada, S., Cunningham, K. D., Flax, E. L., Wickham, J., Reed, J. C., Byrd, J. C., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403388 · Cited by 136
Aggerholm, A., Guldberg, P., Hokland, M., & Hokland, P. (1999) · PubMed · Cited by 134
Selective Growth Inhibition of Tumor Cells by a Novel Histone Deacetylase Inhibitor, NVP-LAQ824
Atadja, P. W., Gao, L., Kwon, P. O., Trogani, N., Walker, H., Hsu, M., Yeleswarapu, L., Chandramouli, N., Perez, L. B., Versace, R. W., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2043 · Cited by 133
Rahmani, M., Yu, C., Dai, Y., Reese, E., Ahmed, W. B., Dent, P., & Grant, S. (2003) · PubMed · Cited by 132
Transcription factor fusions in acute leukemia: variations on a theme
Scandura, J. M., Boccuni, P., Cammenga, J., & Nimer, S. D. (2002) · Oncogene · doi:10.1038/sj.onc.1205315 · Cited by 132
Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia
Kantarjian, H., O'Brien, S., Keating, M. J., Beran, M., Estey, E. H., Giralt, S. A., Kornblau, S. M., Rios, M., Vos, D. D., & Talpaz, M. (1997) · Leukemia · doi:10.1038/sj.leu.2400796 · Cited by 130
Shen, L., Toyota, M., Kondo, Y., Obata, T., Daniel, S., Pierce, S. A., Imai, K., Kantarjian, H. M., Issa, J. J., & Garcia‐Manero, G. (2003) · Blood · doi:10.1182/blood-2002-08-2466 · Cited by 128
Bali, P., George, P., Cohen, P. S., Tao, J., Guo, F., Sigua, C. A., Vishvanath, A., Scuto, A., Annavarapu, S., Fiskus, W. C., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0210 · Cited by 128
Self-citationThe Clinical Application of Targeting Cancer through Histone Acetylation and Hypomethylation
Gilbert, J., Gore, S. D., Herman, J. G., & Carducci, M. A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0297 · Cited by 121
Lee, B. I., Park, S. H., Kim, J. W., Sausville, E. A., Kim, H. T., Nakanishi, O., Trepel, J. B., & Kim, S. J. (2001) · PubMed · Cited by 120
Zhang, X. D., Gillespie, S., Borrow, J. M., & Hersey, P. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00509-4 · Cited by 115
Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate
Qiu, L., Kelso, M. J., Hansen, C. P., West, M. L., Fairlie, D. P., & Parsons, P. G. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690493 · Cited by 115
Yao, Q., Nishiuchi, R., Li, Q., Kumar, A. R., Hudson, W. A., & Kersey, J. H. (2003) · PubMed · Cited by 111
Promoter methylation of cyclin D2 gene in gastric carcinoma
Oshimo, Y., Nakayama, H., Ito, R., Kitadai, Y., Yoshida, K., Chayama, K., & Yasui, W. (2003) · International Journal of Oncology · doi:10.3892/ijo.23.6.1663 · Cited by 109
Wittmann, S., Bali, P., Donapaty, S., Nimmanapalli, R., Guo, F., Yamaguchi, H., Huang, M., Jove, R., Wang, H., & Bhalla, K. N. (2003) · PubMed · Cited by 107
Self-citationEpigenetic Regulation of Gelsolin Expression in Human Breast Cancer Cells
Mielnicki, L. M., Ying, A., Head, K. L., Asch, H. L., & Asch, B. B. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4461 · Cited by 104
Gore, S. D., Weng, L. J., Zhai, S., et al. (2001) · PubMed · Cited by 102
Bouchard, J., & Momparler, R. L. (1983) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)14371-x · Cited by 102
Molecular, cellular and animal pharmacology of 5-AZA-2′-deoxycytidine
Momparler, R. L. (1985) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(85)90053-1 · Cited by 95
Sasakawa, Y., Naoe, Y., Inoue, T., Sasakawa, T., Matsuo, M., Manda, T., & Mutoh, S. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01261-3 · Cited by 93
The Discovery of NVP-LAQ824: From Concept to Clinic
Remiszewski, S. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033456675 · Cited by 88
Chen, Z., Clark, S., Birkeland, M., Sung, C.-M., Lago, A., Liu, R., Kirkpatrick, R., Johanson, K., Winkler, J. D., & Hu, E. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00322-1 · Cited by 87
Rosato, R. R., Wang, Z., Gopalkrishnan, R. V., Fisher, P. B., & Grant, S. (2001) · International Journal of Oncology · doi:10.3892/ijo.19.1.181 · Cited by 87
Issa, J. J. (2003) · Current Opinion in Oncology · doi:10.1097/00001622-200311000-00007 · Cited by 80
Brinkmann, H., Dahler, A. L., Popa, C., Serewko-Auret, M. M., Parsons, P. G., Gabrielli, B. G., Burgess, A., & Saunders, N. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100206200 · Cited by 79
Nguyen, D. M., Schrump, W. D., Chen, G. A., Tsai, W. S., Nguyen, P., Trepel, J. B., & Schrump, D. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0901-3 · Cited by 77
Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumors.
Aparicio, A. M., & Weber, J. S. (2002) · PubMed · Cited by 76
Teofili, L., Martini, M., Luongo, M., Diverio, D., Capelli, G., Breccia, M., Coco, F. L., Leone, G. G. M., & Larocca, L. M. (2003) · Leukemia · doi:10.1038/sj.leu.2402907 · Cited by 74
DiGiuseppe, J. A., Weng, L.-J., Yu, K.-H., Fu, S., Kastan, M., Samid, D., & Gore, S. D. (1999) · Leukemia · doi:10.1038/sj.leu.2401471 · Cited by 72
Dimerization: a versatile switch for oncogenesis
So, C. W. E., & Cleary, M. L. (2004) · Blood · doi:10.1182/blood-2004-03-0992 · Cited by 71
Sitailo, S., Sood, R., Barton, K., & Nucifora, G. (1999) · Leukemia · doi:10.1038/sj.leu.2401585 · Cited by 71
Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma
Koduru, P., Zariwala, M. G., Soni, M., Gong, J., Xiong, Y., & Broome, J. (1995) · Blood · doi:10.1182/blood.v86.8.2900.2900 · Cited by 68
Momparler, R. L., Bouchard, J., & Samson, J. (1985) · Leukemia Research · doi:10.1016/0145-2126(85)90123-7 · Cited by 67
Rosato, R. R., Almenara, J. A., Cartee, L., Betts, V., Chellappan, S., & Grant, S. (2002) · PubMed · Cited by 66
Kurz, E. U., Wilson, S. E., Leader, K. B., Sampey, B. P., Allan, W. P., Yalowich, J. C., & Kroll, D. J. (2001) · PubMed · Cited by 65
Targeted therapies in myeloid leukemia
John, A. M., Thomas, N. S. B., Mufti, G. J., & Padua, R. A. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.11.006 · Cited by 62
Inhibition of Mitogenesis in Balb/c-3T3 Cells by Trichostatin A
Wharton, W., Savell, J. G., Cress, W. D., Seto, E., & Pledger, W. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005600200 · Cited by 59
Weisberg, E., Catley, L. P., Kujawa, J., Atadja, P. W., Remiszewski, S., Fuerst, P., Cavazza, C., Anderson, K. C., & Griffin, J. D. (2004) · Leukemia · doi:10.1038/sj.leu.2403519 · Cited by 59
Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro
Coffey, D. C., Kutko, M. C., Glick, R. D., Swendeman, S. L., Butler, L. M., Rifkind, R. A., Marks, P. A., Richon, V. M., & LaQuaglia, M. P. (2000) · Medical and Pediatric Oncology · doi:10.1002/1096-911x(20001201)35:6<577::aid-mpo18>3.0.co;2-3 · Cited by 58
Treatment of myelodysplastic syndromes with 5-azacytidine
Gryn, J. F., Zeigler, Z. R., Shadduck, R. K., LISTER, J. W., Raymond, J. M., Sbeitan, I., Srodes, C., Meisner, D. J., & Evans, C. D. (2002) · Leukemia Research · doi:10.1016/s0145-2126(02)00028-0 · Cited by 54
Sheikhha, M. H., Tobal, K., & Yin, A. L. J. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03458.x · Cited by 53
Chitambar, C. R., Libnoch, J. A., Matthaeus, W. G., Ash, R. C., Ritch, P. S., & Anderson, T. (1991) · American Journal of Hematology · doi:10.1002/ajh.2830370207 · Cited by 53
Gao, N., Dai, Y., Rahmani, M., Dent, P., & Grant, S. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.002014 · Cited by 52
Chromatin Modification, Leukaemia and Implications for Therapy
Jones, L. K., & Saha, V. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03586.x · Cited by 51
Myelodysplastic syndrome: review of the cytogenetic and molecular data
Mhawech, P., & Saleem, A. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00101-9 · Cited by 51
Cell cycle effects and cellular pharmacology of 5-AZA-2?-deoxycytidine
Momparler, R. L., Samson, J., Momparler, L. F., & Rivard, G. (1984) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00269027 · Cited by 51
Witzig, T. E., Timm, M., Stenson, M. J., Svingen, P. A., & Kaufmann, S. H. (2000) · PubMed · Cited by 49
Wolff, L., Garin, M. T., Koller, R. P., Bies, J., Liao, W., Malumbres, M., Tessarollo, L., Powell, D., & Perella, C. M. (2003) · Oncogene · doi:10.1038/sj.onc.1207092 · Cited by 43
Mode of action and effects of 5-azacytidine and of its derivatives in eukaryotic cells
Veselý, J. (1985) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(85)90012-9 · Cited by 43
Saba, H. I., Rosenfeld, C. S., Issa, J. J., DiPersio, J. F., Raza, A., Klimek, V. M., Slack, J. L., de Castro, C., Mettinger, K. L., & Kantarjian, H. M. (2004) · Blood · doi:10.1182/blood.v104.11.67.67 · Cited by 41
Yu, K., Weng, L.-J., Fu, S., Piantadosi, S., & Gore, S. D. (1999) · Leukemia · doi:10.1038/sj.leu.2401468 · Cited by 35
Huang, Y., & Waxman, S. (1998) · PubMed · Cited by 33
Turner, B. M. (2003) · Nature Cell Biology · doi:10.1038/ncb0503-390 · Cited by 32
Ivanov, M., Lamrihi, B., Moshe Szyf, A., Scherman, D., & Bigey, P. (2003) · The Journal of Gene Medicine · doi:10.1002/jgm.438 · Cited by 31
Tschan, M. P., Vonlanthen, S., Cajot, J., Peters, U. R., Oppliger, E., Betticher, D. C., Yarbrough, W. G., Fey, M. F., & Tobler, A. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109097728 · Cited by 16
(2001) · PubMed
Cited by
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
Marks, P. A., & Breslow, R. (2007) · Nature Biotechnology · doi:10.1038/nbt1272 · Cited by 1,196
Roles of the EZH2 histone methyltransferase in cancer epigenetics
Simon, J. A., & Lange, C. A. (2008) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2008.07.010 · Cited by 855
Cellular senescence and tumor suppressor gene p16
Rayess, H., Wang, M. B., & Srivatsan, E. S. (2012) · International Journal of Cancer · doi:10.1002/ijc.27316 · Cited by 825
Metadata
- Authors
- Bhalla, K. N.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-06-10
- Volume
- 23
- Issue
- 17
- Pages
- 3971-3993
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2140587516
- Cited by
- 308
- References
- 274
- FWCI
- 10.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.